E

Editas Medicine
D

EDIT

1.32000
USD
-0.01
(-0.75%)
Market Closed
Volume
173,620
EPS
-3
Div Yield
-
P/E
-1
Market Cap
108,963,491
OverviewSignalsIdeasNews
Related Instruments
    ALNY
    ALNY
    6.675
    (2.79%)
    245.505 USD
    B
    BEAM
    2.190
    (8.16%)
    29.020 USD
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    N
    NTLA
    0.120
    (0.99%)
    12.190 USD
    R
    RGEN
    -2.045
    (-1.39%)
    144.570 USD
    S
    SGMO
    0.17500
    (7.56%)
    2.49000 USD
    TMO
    TMO
    7.55
    (1.46%)
    524.03 USD
    VRTX
    VRTX
    0.58
    (0.15%)
    397.15 USD
    More
News

Title: Editas Medicine

Sector: Healthcare
Industry: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.